| Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. | |
| | |
MedLine Citation:
|
PMID: 11587809 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Nasalflu Berna is a trivalent influenza virus vaccine for active immunization against influenza by the nasal route. It consists of influenza virosomes which are formulated from inactivated influenza strains and heat-labile toxin from aseptic Escherichia coli bacteria strain, as an adjuvant (HLT). The results of preclinical studies in ferrets, baboons, minipigs, mice and rabbits are presented here, and issues concerning route of administration, mechanism of action (preventing the disease and halting further spread of the disease), and the specific safety issues of the adjuvant itself (possible neurological activity of HLT) are examined. No clinical signs were detected in the animals, and hematological values were in the normal range. In particular, there was no evidence of any systemic adverse reaction, including sensitization to the test substances, and no evidence of possible neurological activity of the HLT. Further clinical studies in humans conducted over five influenza seasons using this virosome-formulated intranasal vaccine, elicited high levels of influenza-specific hemagglutination inhibition IgG antibody titers to the strains incorporated in the administered vaccine. In addition, IgA antibodies were also elicited in the nasal mucosa, and in the saliva. In addition to the systemic IgG antibody titers, the nasal mucosal IgA antibody response may provide additional local protection by the inhibition of viral replication and further spread in the respiratory tract. Nasalflu was well tolerated by most of the vaccinated subjects, both in terms of nasal symptoms and possible vaccination-mediated systemic symptoms. Both local and systemic symptoms were primarily mild, with only an occasional subject reporting moderate intensity. Out of four serious adverse events seen during the clinical development, only one was thought to be remotely related to the test vaccine.Nasalflu, developed by the Swiss Serum and Vaccine Institute, is a novel, highly immunogenic and safe influenza subunit vaccine which is easily administered as a nasal spray. This new route of administration is likely to increase compliance to vaccination, and could become an important tool to promote vaccination in population groups which show high resistance to vaccination. |
| | |
Authors:
|
R Glueck |
Related Documents
:
|
20369059 - Immunogenicity of three different influenza vaccines against homologous and heterologou... 17570109 - Antibody responses to vaccinia membrane proteins after smallpox vaccination. 9004449 - A virosome vaccine antigen delivery system does not stimulate an antiphospholipid antib... 1104969 - Immunogenicity of escherichia coli o antigen in upper urinary tract infection. 17521369 - The delivery site of a monovalent influenza vaccine within the respiratory tract impact... 9240689 - Immunogenicity and reactogenicity of influenza subunit vaccines produced in mdck cells ... 23121399 - Conjugate vaccine introduction in the african meningitis belt: meeting surveillance obj... 21226559 - Predictors of influenza vaccination among emergency medical services personnel. 8045739 - Measles immunity in israeli young adults: effects of second immunization at 18 years of... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Vaccine Volume: 20 Suppl 1 ISSN: 0264-410X ISO Abbreviation: Vaccine Publication Date: 2001 Oct |
Date Detail:
|
Created Date: 2001-10-05 Completed Date: 2002-01-10 Revised Date: 2009-11-03 |
Medline Journal Info:
|
Nlm Unique ID: 8406899 Medline TA: Vaccine Country: England |
Other Details:
|
Languages: eng Pagination: S42-4 Citation Subset: IM |
Affiliation:
|
Swiss Serum & Vaccine Institute, 3018, Bern, Switzerland. reinhard.glueck@berna.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adjuvants, Immunologic
/
toxicity* Administration, Intranasal Animals Bacterial Toxins / pharmacokinetics, toxicity* Enterotoxins / pharmacokinetics, toxicity* Escherichia coli Proteins* Ferrets Humans Vaccines / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/Adjuvants, Immunologic; 0/Bacterial Toxins; 0/Enterotoxins; 0/Escherichia coli Proteins; 0/Vaccines; 0/heat-labile enterotoxin, E coli |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: What are the limits of adjuvanticity?
Next Document: Statistical assessment of the association between vaccination and rare adverse events post-licensure...